On October 13, 2025 AbbVie (NYSE: ABBV) reported it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, taking place October 17-21, in Berlin, Germany (Press release, AbbVie, OCT 13, 2025, View Source [SID1234656598]). Data from investigational and approved ADCs across AbbVie’s portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO (Free ESMO Whitepaper) showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio."

Key highlights
AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented:

Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).1 Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.1
Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).2 The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).2
Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC ): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).3
"Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A’s potential in multiple solid tumors and thereby warrant its further clinical investigation."

AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984).

A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.4
In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.5 These data highlight the potential of ctDNA as an early response marker in SCLC.5
A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC.

Details on key presentations at the ESMO (Free ESMO Whitepaper) 2025 Congress are available below and the full abstracts are available via the ESMO (Free ESMO Whitepaper) online program.

Title

Date/Time

Session

Abstract / Presentation Number

Telisotuzumab Adizutecan (ABBV-400; Temab-A) in
Patients With MET-Amplified Advanced Solid Tumors:
Results From a Phase 1 Study

Sunday,
October 19

2:45 – 4:15 PM
CEST

Oral presentation

Proffered paper
session:
Developmental
therapeutics

Room: Bremen
Auditorium – Hall
6.2

918O

Telisotuzumab Adizutecan (ABBV-400; Temab-A) in
Combination With Bevacizumab (Bev) in Patients (Pts)
With 3+ Colorectal Cancer (CRC): Dose Expansion
Results of a Phase 1 Study

Sunday,
October 19

2:45 – 4:15 PM
CEST

Mini oral session
1 : GI tumors,lower
digestive

Room:

Cologne Auditorium
– CityCube A

731MO

Phase 1 Basket Study of Telisotuzumab Adizutecan
(Temab-A), a c-Met Protein-Targeting Antibody-Drug
Conjugate (ADC): Results from Patients (Pts) With
Pancreatic Ductal Adenocarcinoma (PDAC)

Monday,
October 20

8:30 – 10:00
AM CEST

Mini oral session
2 : GI tumours,
upper digestive

Room: Bonn
Auditorium – Hall
7.1c

2214MO

Second progression-free survival (PFS2) and
subsequent treatment in patients (pts) with folate
receptor alpha (FR⍺)-positive platinum-resistant
ovarian cancer (PROC) treated with mirvetuximab
soravtansine (MIRV) vs. investigator’s choice
chemotherapy (ICC): Phase 3 MIRASOL trial

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1068P

Efficacy of ABBV-706 as second-line treatment for
patients with platinum-refractory/resistant small cell
lung cancer

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

2777P

Real World Characteristics and Outcomes of Patients
with Third Line or Later Metastatic Colorectal Cancer:
Magnetic-101 Study Results

Sunday,
October 19

12:00 – 12:45
PM CEST

E-Poster

873eP

ABBV-706, a Seizure-Related Homolog Protein 6
(SEZ6)-Targeting Antibody-Drug Conjugate (ADC), in
Patients (Pts) With Relapsed/Refractory (R/R) Small
Cell Lung Cancer (SCLC): Circulating Biomarker and
Molecular Response Analyses

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

2778P

Seizure Related 6 Homolog (SEZ6) Expression
Pattern and Prognostic Impact in a Real-World Cohort
of Patients With Small Cell Lung Cancer

Saturday,
October 18

12:00 – 12:45
PM CEST

E-Poster

2796eP

Companion diagnostic assay for c-Met protein
overexpression (OE) to identify patients (pts) who may
benefit from telisotuzumab vedotin (Teliso-V)

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1951P

Treatment outcomes in patients (pts) with advanced c-
Met overexpressing (OE) EGFR wildtype (WT)
nonsquamous (NSQ) NSCLC who had telisotuzumab
vedotin (Teliso-V) dose modifications in the
LUMINOSITY trial

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1948P

Ocular surface disorders in patients with c-Met protein-
overexpressing NSCLC treated with telisotuzumab
vedotin in the LUMINOSITY study

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1950P

METRIX: International Real-World Study of c-Met
Protein Overexpression in Patients With Advanced
/Metastatic NSCLC

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1923P

Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

Elahere (mirvetuximab soravtansine) and Emrelis (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

Additional information on AbbVie clinical trials is available at View Source